IDEXX Laboratories, Inc. $IDXX Shares Purchased by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA boosted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 67.2% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 287,937 shares of the company’s stock after buying an additional 115,698 shares during the period. Pictet Asset Management Holding SA’s holdings in IDEXX Laboratories were worth $161,763,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Virtus Advisers LLC acquired a new position in IDEXX Laboratories during the third quarter worth $26,000. SHP Wealth Management acquired a new stake in IDEXX Laboratories in the fourth quarter valued at $26,000. Park Place Capital Corp acquired a new stake in IDEXX Laboratories in the fourth quarter valued at $29,000. WealthCollab LLC purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter worth $30,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of IDEXX Laboratories during the 3rd quarter worth $36,000. 87.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Stifel Nicolaus decreased their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Citigroup assumed coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price on the stock. Weiss Ratings raised shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday. Finally, UBS Group reduced their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Seven research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $551.50 on Monday. IDEXX Laboratories, Inc. has a fifty-two week low of $506.91 and a fifty-two week high of $769.98. The stock has a market cap of $43.50 billion, a P/E ratio of 40.61, a P/E/G ratio of 3.02 and a beta of 1.56. The business has a fifty day simple moving average of $558.79 and a 200-day simple moving average of $614.13. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the previous year, the company posted $2.91 EPS. The business’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.